Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

Cancer

Volumn 120, Issue 1, 2014, Pages 7-10

  Becker, Andreas ^a,b   Eichelberg, Christian ^a   Sun, Maxine ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Martini Clinic Prostate Cancer Center   (Germany)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB;

CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; FALSE POSITIVE RESULT; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR GROWTH; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE;

EID: 84890772195     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28378     Document Type: Review

References (29)

1. Parton M, Gore M, Eisen T,. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006; 24: 5584-5592. (Pubitemid 46631339)
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590.
3. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124. (Pubitemid 46089672)
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134. (Pubitemid 46089673)
5. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008; 26: 5422-5428.
6. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-2111. (Pubitemid 350296300)
7. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28: 2144-2150.
8. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-2143.
9. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281. (Pubitemid 46849157)
10. Motzer RJ, Escudier B, Oudard S, et al. Record-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-4265.
11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-1068.
12. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013; 49: 1287-1296.
13. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-1939.
14. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013; 14: 552-562.
15. Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M,. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer. 2001; 91: 2033-2038. (Pubitemid 32479191)
16. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005; 23: 8664-8670. (Pubitemid 46211509)
17. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ,. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009; 27: 2766-2771.
18. Buyse M,. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J. 2009; 15: 421-425.
19. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R,. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst. 2010; 102: 230-243.
20. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer. 2011; 117: 2637-2642.
21. Halabi S, Rini B, Escudier B, Stadler WM, Small EJ,. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014; 120: 52-60.
22. Korn EL, Freidlin B, Abrams JS,. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011; 29: 2439-2442.
23. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
24. Booth CM, Eisenhauer EA,. Progression-free survival: meaningful or simply measurable? J Clin Oncol. 2012; 30: 1030-1033.
25. Motzer RJ, Eisen T, Hutson TE, et al. Overall survival in patients from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma [abstract]. J Clin Oncol. 2013; 31 (suppl 6):Pages. Abstract 350.
26. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8: 431-440. (Pubitemid 19105891)
27. Beckman M,. More clinical cancer treatments judged by progression-free rather than overall survival. J Natl Cancer Inst. 2007; 99: 1068-1069.
28. Weir CJ, Walley RJ,. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med. 2006; 25: 183-203. (Pubitemid 43141502)
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216. (Pubitemid 30099779)